What this study adds:
- A comprehensive summary of ADME, DDI, Adverse Events (AEs) and
simulated lung exposure for COVID-19 repurposed drugs
- Verified PBPK models that predict changes in drug exposure in various
clinical scenarios to guide dosing information where clinical data are
not possible, especially during this COVID-19 pandemic
- Simulated plasma and lung tissue exposure of drugs to justify broader
recruitment criteria for patients and assess the relevant potency
values from in vitro studies for SARS-CoV-2